Alexion has announced that four members of the company’s C-suite team are set to leave the company, following an internal investigation into sales practices.
Chief financial officer Dave Anderson is among the casualties, who while just joining the company this past December is set to resign in August. Alexion will also lose its R&D chief, Martin Mackay, to retirement. EVP and head of human resources Clare Carmichael and commercial chief Carsten Thiel are leaving as well, with Thiel’s replacement, Brian Goff, already hired.
Alexion has completely remade its executive makeup, which began when former CEO David Hallal lost investor confidence amid sales fraud investigations that demonstrated that the company inappropriately pressured staff to pad sales of its Soliris treatment.
> Read the Wall Street Journal report
Source: Pharmaceutical Manufacturing
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.